Tag: dabigatran

ESC 2017: Case builds for dropping aspirin from triple therapy in...

The RE-DUAL PCI trial indicates that dual therapy with the non-vitamin K antagonist oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim)—and not aspirin—and a P2Y12 inhibitor...

Patient enrolment complete in study assessing use of dabigatran atrial fibrillation...

  Patient enrolment into the international Phase IIIb RE-DUAL PCI study is complete. The study is evaluating the safety and efficacy of dabigatran (Pradaxa, Boehringer...